Notice: This company has been marked as potentially delisted and may not be actively trading. Zafgen (ZFGN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends ZFGN vs. UPB, ANAB, OMER, XERS, SBTX, RAPP, AKBA, ALT, MLYS, and RNACShould you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include Upstream Bio (UPB), AnaptysBio (ANAB), Omeros (OMER), Xeris Biopharma (XERS), Silverback Therapeutics (SBTX), Rapport Therapeutics (RAPP), Akebia Therapeutics (AKBA), Altimmune (ALT), Mineralys Therapeutics (MLYS), and Cartesian Therapeutics (RNAC). These companies are all part of the "medical" sector. Zafgen vs. Upstream Bio AnaptysBio Omeros Xeris Biopharma Silverback Therapeutics Rapport Therapeutics Akebia Therapeutics Altimmune Mineralys Therapeutics Cartesian Therapeutics Upstream Bio (NASDAQ:UPB) and Zafgen (NASDAQ:ZFGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Is UPB or ZFGN more profitable? Upstream Bio's return on equity of 0.00% beat Zafgen's return on equity.Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Zafgen N/A -51.34%-34.55% Do institutionals and insiders believe in UPB or ZFGN? 70.4% of Zafgen shares are held by institutional investors. 14.2% of Zafgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer UPB or ZFGN? Zafgen received 341 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 68.59% of users gave Zafgen an outperform vote. CompanyUnderperformOutperformUpstream BioOutperform Votes4100.00% Underperform VotesNo VotesZafgenOutperform Votes34568.59% Underperform Votes15831.41% Which has stronger valuation & earnings, UPB or ZFGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream BioN/AN/AN/AN/AN/AZafgenN/AN/A-$45.41M-$1.07-3.25 Does the media favor UPB or ZFGN? In the previous week, Upstream Bio had 8 more articles in the media than Zafgen. MarketBeat recorded 8 mentions for Upstream Bio and 0 mentions for Zafgen. Upstream Bio's average media sentiment score of 0.49 beat Zafgen's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media. Company Overall Sentiment Upstream Bio Neutral Zafgen Neutral Do analysts rate UPB or ZFGN? Upstream Bio currently has a consensus price target of $56.50, suggesting a potential upside of 413.64%. Given Upstream Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Upstream Bio is more favorable than Zafgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Zafgen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryUpstream Bio beats Zafgen on 8 of the 11 factors compared between the two stocks. Get Zafgen News Delivered to You Automatically Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZFGN vs. The Competition Export to ExcelMetricZafgenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.40M$6.92B$5.62B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E Ratio-3.6310.1189.6917.66Price / SalesN/A351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book2.585.335.134.73Net Income-$45.41M$157.56M$118.85M$225.42M Zafgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZFGNZafgenN/A$3.48+0.6%N/A-28.8%$130.40MN/A-3.6338UPBUpstream BioN/A$9.92-4.5%$56.50+469.6%N/A$531.71MN/A0.0038Upcoming EarningsNews CoverageGap UpANABAnaptysBio3.6664 of 5 stars$17.46+3.6%$41.45+137.4%-26.9%$531.31M$17.16M-2.87100OMEROmeros4.3735 of 5 stars$8.99+7.4%$22.50+150.3%+158.8%$520.97MN/A-3.89210XERSXeris Biopharma3.8413 of 5 stars$3.47+0.6%$4.87+40.2%+37.2%$517.31M$163.91M-7.71290SBTXSilverback TherapeuticsN/A$14.08+1.4%N/A+136.8%$507.70MN/A-5.8283High Trading VolumeRAPPRapport Therapeutics2.6029 of 5 stars$13.77-0.9%$35.00+154.2%N/A$503.71MN/A0.00N/AUpcoming EarningsShort Interest ↓News CoverageAKBAAkebia Therapeutics3.6567 of 5 stars$2.30-3.4%$7.50+226.1%+28.5%$501.81M$194.62M-10.00430Short Interest ↑ALTAltimmune2.4684 of 5 stars$7.00+0.3%$20.83+197.6%-31.4%$497.84M$430,000.00-4.5250Analyst RevisionMLYSMineralys Therapeutics2.7595 of 5 stars$10.00+0.3%$30.00+200.0%-5.3%$497.70MN/A-3.0628Positive NewsRNACCartesian Therapeutics2.0511 of 5 stars$19.42+1.1%$42.86+120.7%-19.1%$493.66M$26M-0.3764Analyst ForecastGap Up Related Companies and Tools Related Companies UPB Alternatives ANAB Alternatives OMER Alternatives XERS Alternatives SBTX Alternatives RAPP Alternatives AKBA Alternatives ALT Alternatives MLYS Alternatives RNAC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZFGN) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
